---
title: "12 Health Care Stocks Moving In Thursday's Pre-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290830160.md"
description: "In Thursday's pre-market session, several healthcare stocks saw significant movement. Gainers included Adicet Bio (+22.9%), Bio-Techne (+19.83%), and TELA Bio (+14.65%). Conversely, ARS Pharmaceuticals dropped 28.9%, Passage Bio fell 22.11%, and Valion Bio decreased 14.63%. The report highlights specific percentage changes and market capitalizations for these active securities."
datetime: "2026-06-25T12:05:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290830160.md)
  - [en](https://longbridge.com/en/news/290830160.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290830160.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Thursday's Pre-Market Session

### Gainers

-   **Adicet Bio** (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-market session. The market value of their outstanding shares is at $77.1 million.
-   **Bio-Techne** (NASDAQ:TECH) stock moved upwards by 19.83% to $70.55. The market value of their outstanding shares is at $9.1 billion.
-   **TELA Bio** (NASDAQ:TELA) stock increased by 14.65% to $0.86. The market value of their outstanding shares is at $33.5 million.
-   **Lakewood-Amedex** (NASDAQ:LABT) shares rose 11.55% to $4.15. The company's market cap stands at $6.5 million.
-   **Incannex Healthcare** (NASDAQ:IXHL) shares increased by 10.15% to $3.58. The market value of their outstanding shares is at $38.8 million.
-   **Scilex Holding** (NASDAQ:SCLX) shares rose 10.05% to $7.55. The market value of their outstanding shares is at $48.2 million.

### Losers

-   **ARS Pharmaceuticals** (NASDAQ:SPRY) stock declined by 28.9% to $7.49 during Thursday's pre-market session. The company's market cap stands at $1.0 billion.
-   **Passage Bio** (NASDAQ:PASG) shares declined by 22.11% to $4.58. The market value of their outstanding shares is at $18.8 million.
-   **Valion Bio** (NASDAQ:VBIO) stock decreased by 14.63% to $0.46. The market value of their outstanding shares is at $1.7 million.
-   **Profusa** (NASDAQ:PFSA) stock decreased by 14.16% to $0.11.
-   **Pulsenmore** (NASDAQ:PLSM) shares fell 12.14% to $5.79. The market value of their outstanding shares is at $42.8 million.
-   **Azitra** (AMEX:AZTR) shares decreased by 10.86% to $0.19. The market value of their outstanding shares is at $3.4 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [TELA.US](https://longbridge.com/en/quote/TELA.US.md)
- [PASG.US](https://longbridge.com/en/quote/PASG.US.md)
- [SPRY.US](https://longbridge.com/en/quote/SPRY.US.md)
- [TECH.US](https://longbridge.com/en/quote/TECH.US.md)
- [ACET.US](https://longbridge.com/en/quote/ACET.US.md)
- [VBIO.US](https://longbridge.com/en/quote/VBIO.US.md)
- [LABT.US](https://longbridge.com/en/quote/LABT.US.md)
- [IXHL.US](https://longbridge.com/en/quote/IXHL.US.md)
- [SCLX.US](https://longbridge.com/en/quote/SCLX.US.md)
- [PFSA.US](https://longbridge.com/en/quote/PFSA.US.md)
- [PLSM.US](https://longbridge.com/en/quote/PLSM.US.md)
- [AZTR.US](https://longbridge.com/en/quote/AZTR.US.md)
- [NVACW.US](https://longbridge.com/en/quote/NVACW.US.md)

## Related News & Research

- [Adicet Bio wins FDA IND clearance for ADI-212 prostate cancer trial](https://longbridge.com/en/news/297226436.md)
- [Bio-Techne’s Restrictive Merger Terms and Heavy Termination Fee Threaten Competitive Bidding and Future Deal Leverage](https://longbridge.com/en/news/296994108.md)
- [Adicet Bio, Inc. (NASDAQ:ACET) Given Consensus Rating of "Moderate Buy" by Analysts](https://longbridge.com/en/news/296801308.md)
- [Pentwater Capital Management LP Takes Position in Bio-Techne Corp $TECH](https://longbridge.com/en/news/297162508.md)
- [Keep An Eye On FSport As Insider Stock Selling Hits kr7.2m](https://longbridge.com/en/news/297122777.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**